Immunogenik, Inc.

Gainesville, FL

UEI
XGX9CKVE5N68
CAGE
9TCP5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Joint Venture Women Owned Small Business
  • Woman Owned Small Business
  • Woman Owned Business
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
8967 SW 66th Pl, Gainesville, FL 32608, USA
Website
immunogenik.com
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Immunogenik, Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Enhance cancer therapeutics with 3-in-1 car t cells - project summary recent evidence highlights the significant role of… Grant · R41CA301978 National Cancer Institute $398,997
Advancing cancer therapy: developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305 - project… Grant · R41CA298020 National Cancer Institute $398,997

Quick answers

What is Immunogenik, Inc.'s UEI?

Immunogenik, Inc.'s Unique Entity ID (UEI) in SAM.gov is XGX9CKVE5N68.

What is Immunogenik, Inc.'s CAGE code?

Immunogenik, Inc.'s CAGE code is 9TCP5.

What is Immunogenik, Inc.'s primary NAICS code?

Immunogenik, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Immunogenik, Inc. located?

Immunogenik, Inc.'s physical address in SAM.gov is 8967 SW 66th Pl, Gainesville, FL 32608, USA.

Is Immunogenik, Inc. registered in SAM.gov?

Yes. Immunogenik, Inc.'s SAM.gov registration is active through December 9, 2026.

What is Immunogenik, Inc.'s most recent federal award?

Immunogenik, Inc.'s most recent federal grant award is Enhance cancer therapeutics with 3-in-1 car t cells - project summary recent evidence highlights the significant role of… (R41CA301978), from National Cancer Institute, on July 1, 2025.

On GovTribe

See Immunogenik, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login